Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




Viacom Ahead of Zacks Estimate – Analyst Blog

Zacks Market Commentaries (November 3rd, 2009) Writes:
Viacom Inc. (VIA.B) today declared encouraging results for the third quarter. Quarterly net income from continuing operation was $443 million or 73 cents per share, compared to $385 million or 62 cents per share in the prior-year quarter. However, third-quarter adjusted (excluding one-time discrete tax benefit) EPS was 61 cents significantly above the Zacks Consensus Estimate of 55 cents. This is mainly due to soaring increase in operating profit and effective cost management. Quarterly revenues of $3.32 billion was down 3% year over year but was in line with the Zacks Consensus Estimate.   Operating income was $784 million, up 14% year over year driven by the solid performance of the Filmed Entertainment segment. At the end of the reported quarter, Viacom had $249 million of cash & cash equivalent and $6,852 million of outstanding debt on its balance sheet compared to $792 million of cash & cash ...

Zacks Bull and Bear of the Day Highlights: Pozen, Inc., Rite Aid Corporation, Hasbro Inc., Mattel Inc. and JAKKS Pacific Inc. – Press Releases

Zacks Market Commentaries (October 20th, 2009) Writes:

For Immediate Release

Chicago, IL – October 20, 2009 – Zacks Equity Research highlights Pozen, Inc. (POZN) as the Bull of the Day and Rite Aid Corporation (RAD) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Hasbro Inc.(HAS), Mattel Inc. (MAT) and JAKKS Pacific Inc.(JAKK).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676

Here is a synopsis of all five stocks:

Bull of the Day:

Pozen, Inc. (POZN) is one of our top-picks for small-cap biotech. We see the fundamentals as strong and the valuation as low.

We are pleased to see the NDA for Vimovo (PN-400) filed and now accepted by the U.S. FDA. FDA acceptance earned Pozen a $10 million milestone from AstraZeneca in August. We expect sales of Treximet to ramp in the coming quarters now that the groundwork has been

...

Hasbro Surpasses Zacks Estimate – Analyst Blog

Zacks Market Commentaries (October 19th, 2009) Writes:
Hasbro Inc.’s (HAS) third quarter earnings of 99 cents per share were well ahead of the Zacks Consensus Estimate of 91 cents, reflecting a drop in costs and demand for its movie-based toys. The company had earned 89 cents per share in the year-ago period. Net revenues for the quarter decreased 1.7% to $1.28 billion from the prior-year quarter. Excluding the adverse impact from a stronger dollar, revenues were up 1% in the quarter. Results reflected challenging economic environment, though the Transformers and G.I. Joe experienced strong demand. However, gross margin increased 110 basis points from a year ago to 57.0%. Third quarter results include a 3 cents per share dilutive impact from the company’s investment in its joint venture with Discovery Communications and initial investments in Hasbro’s virtual studio. Operating profit was $230.7 million, up 6.8% year-over-year. Operating margin increased 140 basis points over ...

Earnings Preview for Hasbro – Analyst Blog

Zacks Market Commentaries (October 16th, 2009) Writes:
Hasbro Inc. (HAS) is expected to release its third quarter results on Oct 19. The Zacks Consensus Estimate is pegged at 91 cents per share. The company had reported earnings of 89 cents per share in the year-ago period.  Hasbro’s second quarter results of 26 cents per share were three pennies ahead of the Zacks Consensus Estimate of 23 cents, reflecting strong sales of Transformers and G.I. Joe toys, both tied to blockbuster summer movies. The company also reaped the benefits of its cost curtailment initiatives.  At the time of the last earnings release, management had stated that the joint venture investment with Discovery Communications will not be as dilutive to 2009 and 2010 earnings as previously forecasted. The company had at that time expected that the dilution to 2009 earnings will be in the range of 15 to 20 cents per share, compared to the ...

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.